Cardiovascular Drugs Market Overview, Analysis and Market Growth
- Get link
- X
- Other Apps
Hypertension, rheumatic heart disease, ischemic heart disease, inflammatory heart disease, and cerebrovascular heart disease are some of the most common cardiovascular illnesses. Angina, hypertrophy, and heart failure are all major complications of hypertensive heart disease. High blood pressure in the heart's arteries and muscles promotes narrowing of the arteries, as well as thickening and enlargement of the heart. The global cardiovascular medicine market is primarily driven by increased heart disease prevalence, as well as an ageing population and lifestyle-related disorders. Drugs for the treatment and prevention of cardiovascular disorders are needed to cater to the growing population suffering from these diseases. Another factor projected to drive the global cardiovascular drugs market is an increase in the number of diabetes patients. According to the American Diabetes Association, 30.3 million Americans (9.4% of the total population) had diabetes in 2015.
Increasing R&D activities to
launch new products is expected to support in growth of the cardiovascular
drugs market
The
cardiovascular pharmaceuticals market into five regions: North America, Latin
America, Europe, Asia Pacific, Africa, and the Middle East. The global
cardiovascular pharmaceuticals market is oligopolistic, with a few companies
controlling the majority of the market. Key market players use a variety of
techniques to maintain their market position, including new product releases
and alliances. For example, in December 2017, Medicure Inc., a Canadian
pharmaceutical company, obtained a seven-year exclusive licence to market and
sell a cardiovascular drug for the treatment of primary hyperlipidemia or mixed
dyslipidemia in the United States and its territories through its subsidiary
Medicure International Inc. The US Food and Drug Administration (FDA) approved
Sun Pharmaceutical Industries' subsidiary in the United States to sell generic
versions of its Coreg CR in October 2017. Coreg CR is a medication that is used
to treat a variety of cardiac problems, including high blood pressure and heart
failure. Takeda Pharmaceutical Company Limited and Cardurion Pharmaceuticals
announced their collaboration in August 2017 to develop next-generation
therapeutics for the treatment of cardiovascular disorders and heart failure.
- Get link
- X
- Other Apps
Comments
Post a Comment